PMID- 7744880
OWN - NLM
STAT- MEDLINE
DCOM- 19950612
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 270
IP  - 20
DP  - 1995 May 19
TI  - The human leukocyte antigen A2 interferon-stimulated response element consensus 
      sequence binds a nuclear factor required for constitutive expression.
PG  - 12276-85
AB  - Both constitutive and interferon-inducible enhancer-like elements have been 
      identified previously in the promoter of human leukocyte antigen (HLA) class I 
      genes. One of these sites is termed the interferon-stimulated response element 
      (ISRE). We have tested the function of an ISRE consensus sequence in the human 
      HLA class I gene HLA-A2 and confirmed previous studies that showed that the 
      HLA-A2 ISRE consensus sequence does not mediate a response to interferons. 
      However, deletion of the ISRE consensus sequence caused a several-fold reduction 
      in the constitutive expression of the HLA-A2 gene in K562 and Jurkat cells. 
      Mobility shift assays performed with the HLA-A2 ISRE revealed the presence of a 
      constitutive binding protein (ISRE/CBP). This protein binds specifically to the 
      HLA-A2 ISRE sequence, and binding is not efficiently competed by the ISRE 
      sequences of the HLA-B7 or ISG54 genes. Substitution of the HLA-B7 or ISG54 ISRE 
      sequences for the HLA-A2 ISRE sequence caused a severalfold reduction in the 
      constitutive expression of the HLA-A2 gene. Mass determinations showed the 
      ISRE/CBP to be 105 kDa, different than any previously characterized ISRE binding 
      proteins. We propose that ISRE/CBP is a novel positive transcriptional regulatory 
      factor for the HLA-A2 gene that may contribute to the differential expression of 
      HLA-A versus HLA-B genes.
FAU - Waring, J F
AU  - Waring JF
AD  - Department of Medicine, University of Minnesota, Minneapolis 55455, USA.
FAU - Radford, J E
AU  - Radford JE
FAU - Burns, L J
AU  - Burns LJ
FAU - Ginder, G D
AU  - Ginder GD
LA  - eng
GR  - R01-CA45634/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Carrier Proteins)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-B7 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Base Sequence
MH  - Binding Sites
MH  - Carrier Proteins/isolation & purification/*metabolism
MH  - Consensus Sequence
MH  - *Enhancer Elements, Genetic
MH  - *Gene Expression Regulation/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - *Genes, MHC Class I
MH  - HLA-A2 Antigen/*genetics
MH  - HLA-B7 Antigen/genetics
MH  - Humans
MH  - Interferon-gamma/*pharmacology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
MH  - Leukemia-Lymphoma, Adult T-Cell/pathology
MH  - Molecular Sequence Data
MH  - Molecular Weight
MH  - Mutagenesis, Site-Directed
MH  - Neoplasm Proteins/biosynthesis/genetics
MH  - Protein Binding
MH  - Sequence Alignment
MH  - Tumor Cells, Cultured
EDAT- 1995/05/19 00:00
MHDA- 1995/05/19 00:01
CRDT- 1995/05/19 00:00
PHST- 1995/05/19 00:00 [pubmed]
PHST- 1995/05/19 00:01 [medline]
PHST- 1995/05/19 00:00 [entrez]
AID - S0021-9258(17)47971-3 [pii]
AID - 10.1074/jbc.270.20.12276 [doi]
PST - ppublish
SO  - J Biol Chem. 1995 May 19;270(20):12276-85. doi: 10.1074/jbc.270.20.12276.